NVAX:NASDAQ
Novavax Inc
$9.87
arrow_downward
-1.32%(-0.13) 1D
Sep 18, 10:35:10 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$9.89
High
$10.05
Low
$9.76
Mkt. cap
1.63B
Avg. vol.
5.13M
Volume
859.06K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$9.89
High
$10.05
Low
$9.76
Mkt. cap
1.63B
Avg. vol.
5.13M
Volume
859.06K
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Zacks
·
6 hours ago
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
Yahoo Finance
·
6 hours ago
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
News Corp
·
17 hours ago
Novavax Inc. stock outperforms competitors on strong trading day
Simply Wall Street
·
21 hours ago
Novavax (NVAX) Draws Focus On Policy Reform, Is It 34% Overvalued?
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com